Stéphane Roze

The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making

Andrew Palmer, Stéphane Roze, William J. Valentine et al. · Current Medical Research and Opinion · 2004 · 529 citations · Full text

Pharmacy, Health Policy, Pharmacoeconomics +17

Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes

Julia Ware, Janet M. Allen, Charlotte K. Boughton et al. · New England Journal of Medicine · 2022 · 206 citations · Full text

Medicine, Child Health, Pediatrics +17

Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: Modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom

Andrew Palmer, Stéphane Roze, William J. Valentine et al. · Clinical Therapeutics · 2004 · 127 citations · Full text

Medicine, Pharmacoeconomics, Preventive Medicine +12

Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease

Andrew Palmer, Lieven Annemans, Stéphane Roze et al. · Diabetes Care · 2004 · 93 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +16

Cost‐Effectiveness of Diabetes Case Management for Low‐Income Populations

Todd Gilmer, Stéphane Roze, William J. Valentine et al. · Health Services Research · 2007 · 82 citations · Full text

Pharmacy, Insurance, Pharmacoeconomics +17